Clinical Trials
20 trialsNCT05239624 2026-06-04
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07421700 2026-06-04
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Pfizer
Phase 1/2 Recruiting
NCT07484022 2026-06-03
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Phase 1 Recruiting
NCT06862219 2026-05-28
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Astellas Pharma Inc
Phase 4 Recruiting
NCT06311214 2026-05-27
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06041503 2026-05-22
Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05614739 2026-05-19
FORAGER-1
Eli Lilly and Company
Phase 1 Recruiting
NCT07475806 2026-05-15
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Astellas Pharma Inc
Phase 2 Recruiting
NCT06011954 2026-05-14
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Astellas Pharma Inc
Recruiting
NCT05868265 2026-05-12
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07566156 2026-05-11
EV-309
Astellas Pharma Inc
Phase 3 Recruiting
NCT07087860 2026-05-08
RECIPE-B1
Mayo Clinic
Phase 2 Recruiting
NCT04878029 2026-04-29
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Emory University
Phase 1 Recruiting
NCT07232602 2026-04-24
MK-3475-04D
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07287995 2026-04-23
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT07110038 2026-04-16
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT06553885 2026-04-01
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06891560 2026-03-20
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03547973 2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2 Recruiting